Using a population PK/PD model developed on phase I to select the dose for Phase II: an example with an IgG1 mAb

Authors: Twarogowska M
Conference: SLP MIDD+
Software: Monolix®, Simulx®
Division: Lixoft

Phase II dosing regimen

Dosing of 30 mg/kg Q4W could guarantee >90% inhibition of membrane-bound receptor for 9 in 10 individuals

But…what if

  • weight distribution is different?
  • patients have reduced clearance due to the renal impairment?
  • we start with a loading dose?

Go faster and win with Simulx

By Monika Twarogowska

Download Slides

Presented at SLP MIDD+ Virtual Conference March 3-4, 2021